Daniel Francis is a technical writer and educator specializing in Web3, macroeconomics, and decentralized finance (DeFi). Active in the crypto space since 2017, he uses his expertise in on-chain analytics to produce detailed, evidence-based reports and guides. His work aims to provide clear, practical insights into blockchain technology beyond market hype, supported by certifications from The Blockchain Council.
Bitcoin price analysis is the subject, with Pluang data providing a snapshot of the broader cryptocurrency market. For readers following crypto assets, here is Pluang's market snapshot as of Oct 19, 2026 17:02 WIB: Out of 50 major cryptocurrencies priced on Pluang, 33 rose and 16 fell today. Notable movers include Fantom (FTM) at Rp11.382 with a 1-day change of -2.05% and a typical hold time of 88 days, Theta Network (THETA) at Rp3.369 down 2.04%, and Filecoin (FIL) at Rp18.810 down 2.03% with a Pluang order activity split of 39% Sell and 61% Buy.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
